Chronic Lymphocytic Leukemia

Research

Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic ranks in the top tier of cancer centers in the United States for cancer research. Mayo Clinic is a member of several major national and international collaborative research groups, including the Eastern Cooperative Oncology Group, the Chronic Lymphocytic Leukemia Research Consortium, the North Central Cancer Treatment Group and the Phase 2 Consortium. Because of these affiliations, you have access to leading-edge diagnosis and treatment-related clinical trials at Mayo Clinic.

Mayo Clinic has an extensive research program dedicated to understanding chronic lymphocytic leukemia (CLL) with the hope of improving treatment options. Researchers are playing a lead role in investigating CLL's cause and why the disease is more common in some families. They also are involved in testing the effectiveness of new drug or antibody combinations.

Scientists and blood disorders doctors (hematologists) in the Chronic Lymphoproliferative Disorders Group are working to improve the outlook for people with CLL by identifying risk factors and investigating leukemia's biological process in the body. These clinical trials cover all disease stages ranging from newly diagnosed cases, to recurrent CLL, to treatment-resistant CLL.

Read more about chronic lymphocytic leukemia research at Mayo Clinic on the Hematological Malignancy Program's research page.

Publications

See a list of publications by Mayo Clinic doctors on chronic lymphocytic leukemia on PubMed, a service of the National Library of Medicine.